Top 50 Pharma Companies R&D Pipeline Analysis by Kalorama Information Now Available at MarketPublishers.com

Share Article

New research report “Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016” worked out by Kalorama Information has been recently published by Market Publishers Ltd. The report states that there are 724 projects in development from the top 50 pharmaceutical companies that have the potential to add billions in value to the current pharmaceutical market.

TD The Market Publishers, Ltd

http://marketpublishers.com/

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Currently, there are 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years.

New research report “Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016” worked out by Kalorama Information has been recently published by Market Publishers Ltd.

Report Details:

Title: Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016
Published: August, 2012
Pages: 220
Price: US$ 2,500.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/pharmaceutical-products-of-future-50-company-biopharma-n-traditional-pipeline-analysis-to-2016.html

The research report provides an up-close look at the R&D pipeline of the top 50 pharmaceutical companies worldwide in terms of generated revenues. The study captures key market issues and trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts up to 2016 of the global biopharma market.

Report Contents:

Chapter One: Executive Summary

Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies

Chapter Two: Introduction

Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Expanded Options in Treating Diseases

Chapter Three: Issues and Trends

Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organization
Sustainability in a Changing Pharmaceutical Industry

Chapter Four: Worldwide Pharmaceutical Industry Leaders

Introduction
Pfizer, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Merck & Co., Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Novartis
Overview
Financial Performance and Investments
Late Stage Pipeline
Sanofi
Overview
Financial Performance and Investments
Late Stage Pipeline
Roche Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
GlaxoSmithKline plc
Overview
Financial Performance and Investments
Late Stage Pipeline
AstraZeneca plc
Overview
Financial Performance and Investments
Late Stage Pipeline
Johnson & Johnson
Overview
Financial Performance and Investments
Late Stage Pipeline
Eli Lilly & Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Abbott Laboratories
Overview
Financial Performance and Investments
Late Stage Pipeline
Bristol-Myers Squibb Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Amgen, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Boehringer Ingelheim GmbH
Overview
Financial Performance and Investments
Late Stage Pipeline
Bayer AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Novo Nordis
Overview
Financial Performance and Investments
Late Stage Pipeline
Astellas
Overview
Financial Performance and Investments
Late Stage Pipeline
Daiichi Sankyo
Overview
Financial Performance and Investmen
Late Stage Pipeline
Otsuka
Overview
Financial Performance and Investments
Late Stage Pipeline

Chapter Five: Companies of Interest

Introduction
Merck KGaA
Late Stage Pipeline
Gilead Sciences
...

More new research reports by the publisher can be found at Kalorama Information page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler